EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Improved Outcomes Following the Adoption of Targeted Therapies in High-Risk Chronic Lymphocytic Leukemia Treated in Southern Finland

Tuija Tapaninen, Vesa Lindström, Olivia Hölsä, Emma-Leena Alarmo, Liisa Ukkola-Vuoti, Kimmo Porkka, Oscar Brück

Clinical Lymphoma Myeloma and Leukemia · 2025

DOI: 10.1016/j.clml.2025.12.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Tuija Tapaninen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. Electronic address: tuija.tapaninen@hus.fi. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Molecular Targeted Therapy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Targeted therapies have replaced chemoimmunotherapy for chronic lymphocytic leukemia (CLL), but high-risk CLL patients with TP53 aberrations continue to represent a significant unmet medical need. We profiled treatment patterns, outcomes, and adverse effects in a large, unselected cohort of high-risk CLL patients. PATIENTS AND METHODS: This study retrospectively analyzed clinical data from 1,720 CLL patients diagnosed between 2012 and 2023 within the Helsinki University Hospital district in Southern Finland. We focused on 543 patients who received first-line (1 L) systemic treatment. RESULTS: Of the 543 treated patients, 78 (14.4%) had a TP53 aberrations. A clear shift in treatment patterns occurred after 2018, with targeted therapies comprising over one-third of 1 L regimens. For high-risk patients, ibrutinib use at the 1 L stage rose dramatically after 2018, replacing chemoimmunotherapy as the most common treatment. This change coincided with a marked increase in the median time-to-next-treatment (TTNT) for high-risk patients, from 21.2 months (2012-2017) to 26.0 months (2018-2023). Increased TP53 and IGHV mutation testing rates facilitated more personalized treatment approaches over time. Adverse events were less frequent in patients receiving targeted therapies (62.1%) compared to those on non-targeted regimens (73.5%). Despite these improvements, the median overall survival (OS) for high-risk patients remained challenging at 47.1 months after 1 L treatment. CONCLUSION: The transition to targeted therapies has improved outcomes for high-risk CLL patients. Nevertheless, outcomes for high-risk CLL patients remain inferior to those reported in clinical trials, underscoring the need for real-world evidence and improved therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellMolecular Targeted TherapyAntineoplastic Combined Chemotherapy ProtocolsHumansFinlandMaleFemaleAgedRetrospective StudiesMiddle AgedAged, 80 and overTreatment OutcomeAdult

Stichwörter der Autor:innen

ComorbiditiesImmunoglobulin heavy-chain variable region gene (IGHV) mutationOutcomesReal-world evidence (RWE)Tumor protein p53 aberrations

Autor:innen und Institutionen

  • Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. Electronic address: tuija.tapaninen@hus.fi.
  • Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Medaffcon Oy, Espoo, Finland.
  • AstraZeneca Nordic, Espoo, Finland.
  • iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
  • Hematoscope Lab, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland & Department of Oncology, University of Helsinki, Helsinki, Finland & Department of Clinical Chemistry, HUS Diagnostic Center…

Förderung

  • AstraZeneca

Zitieren

APA

Tapaninen, T., Lindström, V., Hölsä, O., Alarmo, E. L., Ukkola-Vuoti, L., Porkka, K., & Brück, O. (2025). Improved Outcomes Following the Adoption of Targeted Therapies in High-Risk Chronic Lymphocytic Leukemia Treated in Southern Finland. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.12.002

Vancouver

Tapaninen T, Lindström V, Hölsä O, Alarmo EL, Ukkola-Vuoti L, Porkka K, et al. Improved Outcomes Following the Adoption of Targeted Therapies in High-Risk Chronic Lymphocytic Leukemia Treated in Southern Finland. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.12.002

BibTeX
@article{Tapaninen2025,
  author = {Tapaninen, Tuija and Lindström, Vesa and Hölsä, Olivia and Alarmo, Emma-Leena and Ukkola-Vuoti, Liisa and Porkka, Kimmo and Brück, Oscar},
  title = {Improved Outcomes Following the Adoption of Targeted Therapies in High-Risk Chronic Lymphocytic Leukemia Treated in Southern Finland},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  doi = {10.1016/j.clml.2025.12.002}
}
Kostenlos starten →